Helen Chang
About
Helen Chang is from New York City Metropolitan Area. Helen works in the following industries: "Pharmaceuticals". Helen is currently Executive Director, Hospital Marketing / Global Brand Lead- Inomax & Therakos at Mallinckrodt Pharmaceuticals, located in Hampton, New Jersey, United States. Helen also works as Board Member at National Sleep Foundation, a job Helen has held since Jul 2017. In Helen's previous role as a Senior Director, Rare Diseases at Mallinckrodt Pharmaceuticals, Helen worked in Greater New York City Area until Sep 2019. Prior to joining Mallinckrodt Pharmaceuticals, Helen was a Senior Business Consultant at HCH Consulting and held the position of Senior Business Consultant at Greater New York City Area. Prior to that, Helen was a Executive Director, Anti-Infectives at Abbvie (Formerly Forest Laboratories & Allergan) from Apr 2015 to Mar 2017. Helen started working as Product Director, Anti-Infectives at AbbVie (formerly Allergan) in Dec 2011. From Sep 2008 to Dec 2011, Helen was Senior Product Manager, CNS at Allergan. Prior to that, Helen was a Product Manager, Pulmonary at Allergan from Jan 2007 to Jan 2008. Helen started working as Product Manager, Cardiovascular at Allergan in Jan 2005.
Helen Chang's email is available on Finalscout.com free of charge. This database has a wealth of information on over half a billion business professionals and two hundred million companies.
Helen Chang's current jobs
Led global strategic multi-discipline teams to optimize assets by identifying & executing on key projects • Orchestrated global brand strategic and life cycle management plans for device / drug combinations • Identified key investment projects and secured funding through business case presentations • Implemented insights curation process & competitive mitigation planning to maintain share at 75% • Coached marketing team leaders to build and execute plans for double digit growth in CTCL Product: INOmax (inhaled nitric oxide and delivery device combination) Therapeutic Area: Critical care / Respiratory Product: Extracorporal photopheresis (ECP) with Uvadex (Methoxalen) Therapeutic Area: Hematology / Immunology
Helen Chang's past jobs
Prepared cross functional commercial teams for rare disease product launch • Created cross functional go-to-market launch plans • Recommended forecast, spend, and headcount allocation for P&L • Built target product profile & identified key areas for product differentiation Product: Adrabetadex (VTS-270) Therapeutic Area: Niemann-Pick Type C / Rare genetic disorder
Consulted on Pre-launch Planning and Launch Strategy • Crafted launch roadmap for biosimilar oncology product to ensure launch readiness • Directed market sizing and forecasting research projects for early stage product evaluation
Guide commercialization efforts for DALVANCE during company acquisition & integration • Accelerated launch trajectory by redirecting field deployment and channel focus • Launched one-dose formulation resulting in 70% market share • Collaborated with multiple international partners to introduce DALVANCE globally Product: Dalvance (dalbavancin) Therapeutic Area: Infectious Diseases
Launched TEFLARO (IV antibiotic) in the hospital environment • Grew product net sales by 50% by re-focusing on one indication and a new marketing campaign • Researched and executed pricing adjustment which resulted in doubling of revenue • Modeled launch forecast and set weekly product goals to simplify senior management reporting Product: Teflaro (ceftaroline) Therapeutic Area: Infectious Disease
Maintained sales volume of a blockbuster product with targeted promotional spend • Maintained sales forecast and P&L for Lexapro (over $2B in annual sales) • Partnered and managed agencies for the development and execution of promotional campaigns Product: Lexapro (escitalopram) Therapeutic Area: CNS / Depression / Anxiety
Worked with the clinical teams for product development and trial design • Assessed the competitive landscape in chronic obstructive pulmonary disease (COPD) Product: Tudorza (aclidinium) Therapeutic Area: Respiratory / COPD / Pulmonary
Exceeded launch forecast by 12 % by securing buy-in for innovative launch targeting approach - Optimized launch target panel and secured buy-in for innovative approach to sales targeting - Orchestrated seamless launch training execution for a new cardiovascular product Product: Bystolic (nebivolol) Therapeutic Area: Cardiovascular
Launched promotional education initiatives • Overhauled speaker training and advocate development platform among key customers • Negotiated 20% fee reduction with agency to produce campaigns within project budget Product: Ambien (zolpidem) Therapeutic Area: CNS / Sleep Disorders
Created, presented, and executed strategic / tactical plans resulting in 20% increase in overall sales • Planned and launched product into new market achieving 120% to forecast in 3 months • Presented strategic and tactical plans to senior management and negotiated for budget support • Profiled HIV patient advocacy groups and implement direct to patient campaigns Product: Oxandrin (oxandrolone) Therapeutic Area: Metabolic / Burn / Wound
Developed, recommended and presented proposals and tactical plans to clients • Managed status, timeline, and budget within project specs 100% of the time • Directed medical advisory board meetings, speaker’s bureaus, and CME programs
Created database for profiling top institutions – adopted by the whole region as template • Promoted CNS products (Prozac & Zyprexa) to hospitals and psychiatrists • Launched new women's health product (Evista) in hospital and retail markets Products: Zyprexa (olanzapine), Prozac (fluoxetine), & Evista (raloxifene) Therapeutic Area: CNS / Bipolar / Schizophrenia / Depression / Anxiety / Women's Health / Osteoporosis